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Introduction
The incidence of colorectal cancer (CRC) and the number of cancer survivors is increasing. (1) Therefore, it is important to optimize quality of life and long term survival in CRC patients. Vitamin D is a potentially interesting compound as most studies on the association between 25hydroxyvitamin D3 (25(OH)D3) blood levels at diagnosis of CRC and disease outcomes point at higher survival rates with higher levels of 25(OH)D3. (2) Five out of the seven published studies reported hazard ratios ranging between 0.52 and 0.70 for all-cause mortality, (3) (4) (5) (6) (7) while only two did not find a statistically significant association. (8, 9) In addition, daily vitamin D supplementation was associated with a reduced total cancer mortality risk in the general population. (10) Besides, low 25(OH)D3 levels are associated with lower bone density, depression and fatigue in the general population (11) (12) (13) and likely also in CRC patients. Indeed, the prevalence of osteoporosis is higher among cancer patients compared to the general community dwelling population. (14) Furthermore, fatigue and depression are often reported in CRC patients even years after diagnosis and are seriously affecting their quality of life. (15) (16) (17) Vitamin D deficiency (25(OH)D3 levels < 50 nmol/L) (18) at diagnosis were reported to occur in 40-87% of CRC patients, (4) (5) (6) (7) 19) while vitamin D deficiency was reported in 29-58% of healthy individuals of comparable age. (20) (21) (22) (23) This high prevalence of vitamin D deficiency in CRC patients, together with the possible beneficial effects of 25(OH)D3 on quality of life, cancer progression and survival warrants further study on determinants of serum 25(OH)D3 levels to eventually optimize 25(OH)D3 levels in CRC patients.
Several factors may influence 25(OH)D3 blood concentrations in CRC patients. Levels may be influenced by the disease itself and (or) cancer treatment. (24) (25) (26) Vitamin D deficiency was found to be more prevalent in rectal cancer patients compared to colon cancer patients. (27) Furthermore, low J o u r n a l P r e -p r o o f 25(OH)D3 levels were found in CRC patient cohorts in which 25(OH)D3 levels were measured shortly after surgery with a median of 25 nmol/L, (4, 6, 7) while other studies measuring 25(OH)D3 levels before or at diagnosis, thus before surgery, found 25(OH)D3 levels ranging between 43 and 65 nmol/L. (3, 5, 8, 9, 19, 28, 29) In addition, Fakih and colleagues observed that chemotherapy was associated with vitamin D deficiency in CRC patients. (27) To our knowledge, only one small study investigated serum 25(OH)D3 levels prospectively and observed that chemotherapy was associated with a decreased 25(OH)D level in 85 cancer patients. (30) In addition, 25(OH)D3 levels are likely to be modulated by diet and lifestyle. In the general population several lifestyle factors are known to be associated with 25(OH)D3 levels. (20) (21) (22) (23) Higher physical activity levels, the use of vitamin D supplements and dietary vitamin D, (20) (21) (22) (23) 31) and calcium intake (22, 31) were associated with higher 25(OH)D3 levels, while obesity was associated with lower 25(OH)D3 levels. (20) (21) (22) (23) 31) However, the relative importance of these dietary and lifestyle factors in conjunction with clinical factors in CRC patients is presently unknown. In addition, 25(OH)D3 levels may also change over time in CRC patients, because of changes in diet and/or lifestyle due to the diagnosis or treatment. (32) The aim of the current study was to investigate which clinical characteristics in conjunction with demographic and lifestyle factors, were associated with 25(OH)D3 levels at diagnosis and six months later. Besides, we determined which characteristics were associated with changes in 25(OH)D3 levels in the first six months after diagnosis in CRC patients.
Methods

Study population
In total, 1733 CRC patients were recruited in two ongoing prospective cohort studies in the Netherlands between August 2010 and October 2015. Of these patients 1,201 donated a blood sample at diagnosis and 1,002 also six months after diagnosis (Error! Reference source not found.).
The design of the COLON study (33) as well as the EnCoRe study (34) has been described earlier. In short, newly diagnosed CRC patients were recruited directly after diagnosis in 14 hospitals and were followed during and after treatment. Men and women of all ages, with stage I-III CRC were eligible for this analysis. Non-Dutch speaking patients, or patients with a history of CRC or (partial) bowel J o u r n a l P r e -p r o o f resection, chronic inflammatory bowel disease, hereditary CRC syndromes (e.g. Lynch syndrome, Familial Adenomatous Polyposis, Peutz-Jegher), dementia or another mental condition obstructing participation were excluded from the study.
In both studies, the first round of data collection was done at diagnosis. In the COLON study the second data collection time point was six months after diagnosis. For the EnCoRe cohort, data were collected at six weeks and at six months after the end of treatment. To be able to pool the data of both cohorts at comparable time points since CRC diagnosis, we selected the time point in the EnCoRe cohort closest to six months (mean 6.7 months) after diagnosis as the second time point for these analyses.
Blood collection and vitamin D concentrations
For the COLON study, blood samples were obtained during a regular clinical visit in the hospital at diagnosis and six months after diagnosis. Blood samples at diagnosis were collected before start of treatment in 91% of the patients included in these analyses. For the EnCoRe study, blood samples at diagnosis were obtained during a regular clinical visit in the hospital or by a research assistant during a home visit before start of treatment. All blood samples at six weeks and six months after the end of treatment were collected by a research assistant during home visit. All blood samples were obtained in a serum tube, centrifuged and aliquoted into serum and were immediately stored in a freezer at -80°C until further analysis.
For both cohorts, serum 25(OH)D3 levels were measured by isotope-dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) in the Canisius Wilhelmina Hospital, Nijmegen, the Netherlands. (35) The inter-assay coefficients of variation were 5.3%, 3.1% and 2.9% at 25(OH)D3 concentrations of 39.0, 92.5 and 127.0 nmol/L, respectively. Concentrations of 25(OH)D2 were all below the detection limit in our population.
Demographic and lifestyle determinants
Information on height, weight, waist and hip circumference was collected using self-administered questionnaires in the COLON study. In the EnCoRe study, these measurements were performed during home visits. BMI was calculated and categorized as normal weight (BMI<25 kg/m 2 ), overweight (BMI 25-29 kg/m 2 ), or obesity (BMI≥30 kg/m 2 ). The waist-hip ratio (WHR) was calculated by dividing the waist circumference (cm) by the hip circumference (cm). Low education was defined as primary school and lower general secondary education; medium as lower vocational training and higher general secondary education; high as high vocational training and university.
J o u r n a l P r e -p r o o f
Physical activity was assessed using the Short QUestionnaire to ASsess Health-enhancing physical activity (SQUASH) in both cohorts. (36) Activities with a Metabolic Equivalent score (MET score) ≥ 4 were defined as moderate to vigorous physical activity in patients aged between 18 and 55 and MET score ≥ 3 for patients > 55 years.
Habitual dietary intake in the month (COLON study) or year (EnCoRe study) preceding diagnosis was assessed using a semi-quantitative food frequency questionnaire. Six months after diagnosis habitual dietary intake was assessed with a semi-quantitative food frequency questionnaire in the COLON study and a 7 day food diary in the EnCoRe study. Average daily vitamin D (µg/day), calcium (mg/day) and alcohol (g/day) intakes were calculated using the 2011 Dutch food composition (33) in the COLON study. In the EnCoRe study supplement use was assessed by a dietician during a home visit, using standardized forms, and by asking the participants to show the packaging. Supplement use was defined as using supplements at least once a week for at least one month. Additionally, vitamins or minerals that were used once a month, but contained a high dose to cover the intake for a longer period of time (e.g. D-CURE 25.000 IE Cholecalciferol supplementation), were also classified as supplement use.
Clinical information
Clinical data, such as stage of disease, tumour location, tumour differentiation, histological type, date of start treatment, type of treatment (surgery, neo-adjuvant/adjuvant chemotherapy, radiation therapy) and presence of comorbidities (yes/no, diabetes, endocrine disorders, cardiovascular, infectious, gastro-intestinal, muscular and joint, neurologic, pulmonary and urogenital diseases) for both cohorts were derived from the Dutch ColoRectal Audit (DCRA). (38) 
Statistical analyses
To correct for the influence of season on serum vitamin D levels, 25(OH)D3 were adjusted for week of blood collection using the locally weighted polynomial regression (LOESS) method. (39, 40) To obtain interpretable 25(OH)D3 level values, we added the median 25(OH)D3 level to the residuals of the LOESS method. These adjusted 25(OH)D3 levels were used in all subsequent statistical analyses.
Population characteristics were described as percentages and medians with interquartile range [IQR] J o u r n a l P r e -p r o o f for the total study population and stratified by vitamin D deficiency (<50 nmol/L) at diagnosis and six months after diagnosis.
Potential determinants of 25(OH)D3 levels were age (continuous, years), gender (men, women), education (low, medium, high), BMI (normal, overweight, obese and continuous), WHR (continuous), smoking (current, former, never), physical activity (hours moderate-to-vigorous physical activity/week), vitamin D supplement use (yes, no), calcium supplement use (yes, no), dietary vitamin D intake (µg/day, continuous), dietary calcium intake (mg/day, continuous), alcohol intake (g/day, continuous), tumour stage (I, II, III), tumour location (colon, rectum), tumour differentiation (good/moderate, bad), histological type (adenocarcinoma, other), cancer treatment (surgery only, surgery + neo-adjuvant/adjuvant chemotherapy, surgery + radiotherapy, surgery + chemo radiation therapy) and any of the assessed comorbidities (yes, no). Lifestyle and demographic determinants measured at diagnosis were used to assess associations with 25(OH)D3 at diagnosis and determinants measured six months after diagnosis to assess the association with 25(OH)D3 levels six months after diagnosis. Clinical determinants, as stage of disease, type of treatment and having comorbidities were assessed once, shortly after diagnosis.
Linear regression analysis was used to assess which determinants were associated with 25(OH)D3 levels at diagnosis and six months after diagnosis. Only when potential determinants by themselves were statistically significantly associated with 25(OH)D3 levels, they were added to the multivariable model. Determinants added based on univariate regression analyses were gender, BMI, WHR, smoking, physical activity, stage of disease, alcohol intake and vitamin D supplements. The use of calcium supplements was not added to the multivariable model as this was highly correlated with the use of vitamin D supplements (89% of patients using calcium containing supplements were also using vitamin D containing supplements). Additionally, age, having comorbidities, dietary calcium intake and vitamin D intake were added to the multivariable model, which was based on associations with 25(OH)D3 levels being reported in literature (20) (21) (22) (23) 31) for both time points. For the analyses six months after diagnosis, 25(OH)D3 levels at diagnosis and cancer treatment were also added to the models as covariates. Stage was not added to the multivariable model as covariate since type of treatment is dependent on stage of disease and are therefore highly correlated. All models were adjusted for cohort.
Linear mixed models were used to model 25(OH)D3 levels over time to examine changes in 25(OH)D3 levels from diagnosis to six months after diagnosis and to examine which determinants were J o u r n a l P r e -p r o o f associated with these changes. Only patients who donated blood at both time points (n=1002) were included in these analyses. Time was added as a binary variable. As fixed effects we included cohort, age, gender, BMI, smoking status, physical activity, type of treatment, vitamin D supplement use, and dietary intake of vitamin D, calcium and alcohol. All fixed effects were also included in the model as an interaction term with time. Only significant interactions were retained, which included (time*type of treatment, time*WHR, time*vitamin D supplement use and time*comorbidities).
Sensitivity analyses were performed including only patients whose baseline blood sample was collected before treatment commenced (91%).
Statistical analyses were performed in SAS 9.4 (SAS Institute, Cary NC). P-values < 0.05 were considered statistically significant.
Results
Patient characteristics
A total of 1,201 CRC patients were included in the analyses of whom 779 (65%) were men. Median Patients' characteristics stratified by vitamin D deficiency at diagnosis and six months after diagnosis are shown in Table 1 . At both time points, patients who had a deficient 25(OH)D3 status appeared to be more often male, obese, had a lower level of physical activity, a more advanced disease stage, were less often using vitamin D and calcium supplements and had a lower alcohol intake compared with patients who had sufficient levels. In addition, six months after diagnosis patients with deficient 
Determinants of 25(OH)D3 levels
At diagnosis, several demographic, lifestyle and clinical factors were statistically significantly associated with 25(OH)D3 levels ( Table 2 ). In the multivariable analyses, the use of vitamin D supplements, use of calcium supplements, higher dietary vitamin D intake, higher alcohol intake, and being more physically active were associated with higher 25(OH)D3 levels. A higher BMI and WHR, a high education level compared to a low education level, and stage III compared to stage I of disease were associated with lower 25(OH)D3 levels.
Six months after diagnosis, 25(OH)D3 levels at diagnosis, having comorbidities, the use of vitamin D and calcium supplements and dietary vitamin D intake were statistically significantly associated with higher 25(OH)D3 levels. Male gender, a higher BMI, chemotherapy as well as radiotherapy compared to surgery only, and stage III compared to stage I of disease were associated with lower 25(OH)D3 levels.
Determinants of changes in serum 25(OH)D3 levels over time.
After adjustment for other demographic and lifestyle factors 25(OH)D3 levels decreased 6.7 nmol/L (95%CI -9.8; -3.8) more in patients receiving chemotherapy compared to patients who underwent surgery only ( The present study has some limitations. First, although sun exposure is the most important source of vitamin D, and thereby likely a strong determinant, it was not measured in a large part of the study population (COLON study, N=922), and only briefly with one general question (How many days a week were you outside for at least 15 minutes with uncovered hands and face?) in the remaining part (EnCoRe study, n=279). Although we could not investigate sun exposure as a determinant of serum 25(OH)D3 levels, we did adjust for week of blood collection, by which we were able to obtain 25(OH)D3 levels independently of season of blood collection and thereby adjusted partly for sun exposure. In addition, we measured dietary intake using two different methods for part of our population. While an FFQ was used in the COLON study for both time-points, an FFQ (first time-point) and a food diary (second time-point) was used in the EnCoRe study. Although only dietary vitamin D, calcium and alcohol intake were used in these analyses, assessing these by two different methods may have influenced the analysis of changes over time. However, sensitivity analyses in patients of the COLON study, which used one method for both time-points showed similar results regarding dietary vitamin D, calcium and alcohol intake and its relation with 25(OH)D3 levels (data not shown).
Last, some differences in patients' characteristics between the two cohorts were found. Compared to patients included in the COLON study, patients in the EnCoRe study had a higher BMI, had a higher vitamin D and calcium intake via the diet, were more likely to have a good to moderate tumour differentiation and were more likely to suffer from comorbidities at diagnosis. However, we adjusted for cohort in our analyses thereby correcting for these differences.
J o u r n a l P r e -p r o o f
The present study also has important strengths. First of all, this is the largest study that prospectively assessed 25(OH)D3 levels before and after treatment in CRC patients. Our data extend existing evidence regarding lifestyle and treatment characteristics influencing 25(OH)D3 levels. Furthermore, we had data available on many clinical and lifestyle characteristics, making it possible to assess a wide range of lifestyle and clinical determinants that possibly could influence 25(OH)D3 levels.
In conclusion, the most consistent determinants of 25(OH)D3 levels in the first six months after 
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Additional, vitamins or minerals that were used once a week, but containing a high dose to cover the intake for a longer period of time (e.g. vitamin D supplementation), were also included as supplement use.
e: Models for vitamin D supplement use were not corrected for calcium supplement use and vice versa, due to the high correlation between vitamin D and calcium supplement use. 
